Organization · Venture Capital
AN Venture Partners
AN Venture Partners is a global biotech venture capital firm based in Tokyo and San Francisco, focusing on building companies that leverage Japanese scientific research. The firm aims to strengthen Japan's biotech ecosystem through strategic investments and partnerships.
Overview
What AN Venture Partners does
What AN Venture Partners is
AN Venture Partners is a global biotech venture capital firm based in Tokyo and San Francisco, focusing on building companies that leverage Japanese scientific research. The firm aims to strengthen Japan's biotech ecosystem through strategic investments and partnerships.
How it participates in the startup ecosystem
The current public profile supports funder capabilities. Each capability below is shown separately so organization identity and role-specific information do not get conflated.
Operational profile
Organization status and context
Organization status describes the entity itself. Funding and program availability appear within the relevant capability profile.
- Operational status
- Active
- Organization type
- Venture Capital
- Founded
- Founded in 2022
- Approximate age
- About 4 years
- Structured capabilities
- Funder
- Last reviewed
- April 9, 2026
Official channels
Find AN Venture Partners elsewhere
Open the official website or a supported primary organization account.
Capability profile
AN Venture Partners as a funder
Investment thesis
Building blockbuster biotech companies leveraging science from Japan. Focus on company creation and early-stage investments with particular emphasis on Japanese scientific research.
Focus narrative
AN Venture Partners invests in biotech startups that originate from Japanese scientific research, leveraging the resources and expertise of the US biotech ecosystem. The firm collaborates with leading global venture investors to support portfolio companies, enabling robust capitalization and global development.
Value beyond capital
AN Venture Partners provides strategic support to its portfolio companies by leveraging its deep connections within the US biotech ecosystem and its expertise in navigating the complexities of biotech commercialization. The firm partners with leading global venture investors to ensure robust capitalization and facilitate global development for its portfolio companies.
Focus and fit
- Stages
- Pre-seed · Seed · Seed+ · Series A · Series A+
- Regions
- Asia · Global · North America
Availability
- Currently deploying
- Yes
Portfolio and track record
- Recorded portfolio count
- 7
Portfolio context
Notable portfolio companies include: Capacity Bio: Developing a portfolio of small molecule mitophagy inducers. Typewriter Therapeutics: Working on an RNA-based gene writing therapeutic platform. City Therapeutics: Focusing on next-generation engineering of small interfering RNAs (siRNAs). Imbria: Developing novel therapies for patients with life-altering cardiometabolic disorders. PAhR Therapeutics: Innovating treatments for Pulmonary Arterial Hypertension. Crystalys Therapeutics: Advancing innovative therapies for the treatment of gout.
Common questions
What to know about AN Venture Partners
Upseed classifies AN Venture Partners under the Venture Capital organization type. Its current public profile includes funder capabilities.
Source and update disclosure
Know what this page is based on
Source basis
Public organization and program material, official websites, and structured Upseed records.
Last reviewed
April 9, 2026
Known limits
Capability profiles appear only when a structured public profile also contains decision-useful role evidence. Terms and availability can change.
Upseed is an independent guide. It is not affiliated with or endorsed by the organization described on this page.